Top Biotech Companies in Miami, FL (44)
Click Therapeutics, Inc., develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs. As a leading innovator of Digital Therapeutics™, Click delivers accessible, clinically proven, FDA-regulated prescription treatments to the smartphone in your hand. Click’s treatments are defined by a commitment to applying technical and scientific rigor and patient-centric design to the development process. This...
Click Therapeutics's Top Stability & Growth Strengths
Investor Backing & Capital Strength: Evidence indicates a $50 million Series D in April 2026 led by Boehringer Ingelheim, following a Series C in March 2025. This ongoing capital access, including dedicated commercialization funding, signals strong financial support for the next phase of growth.
Strategic Partnerships: Evidence indicates deep relationships with Boehringer Ingelheim and Otsuka, alongside new collaborations such as Ultrahuman for migraine-related technology. These alliances are described as enabling development, regulatory progress, and commercialization pathways across multiple programs.
Product Line Growth: Evidence indicates multiple FDA milestones—Rejoyn for major depressive disorder symptoms (2024), CT-132 for episodic migraine prevention (2025), and Motivista/CT-155 for negative symptoms of schizophrenia (2026)—plus expansion into obesity and cardiometabolic disease via acquired assets. These developments broaden the portfolio across therapeutic areas and advance late-stage candidates toward market.
Smith+Nephew is a global medical technology company. We design and manufacture technology that takes the limits off living. We support healthcare professionals to return their patients to health and mobility, helping them to perform at their fullest potential. From our first employee and founder, T.J. Smith, to our team today, it’s our people who make Smith+Nephew a unique place. Yes, we love...
Smith & Nephew's Top Stability & Growth Strengths
Strong Revenue Growth: Recent results show mid-single-digit underlying growth through 2024–2025, with management reiterating guidance for continued growth in 2026. Early 2026 updates indicate broad-based contributions across units despite some subsegment variability.
Profitability: Trading profit and margins improved, supported by execution of the 12‑Point Plan and the transition to the RISE strategy. Management is guiding to further profit growth alongside higher returns.
Healthy Cash Flow: Free cash flow strengthened in 2025 with guidance for robust generation in 2026. Share repurchases completed and newly announced buybacks signal confidence and disciplined capital allocation.
Lincare is a leading supplier of respiratory-therapy products and services for patients in the home. You can learn more about our extensive suite of products and services by visiting our website. Everywhere we operate, Lincare is working to be a partner in patient care by providing high-quality services and supplies, promoting patient education, and building strong relationships with patients, physicians,...
JEG & Sons specializes in e-commerce channel management, 3PL fulfillment, and product distribution, offering end-to-end solutions for resellers and retailers. They are a leading distributor of IT and electronics products, including phones and accessories.
A trusted partner at nearly three million customer locations, Ecolab (ECL) is the global leader in water, hygiene and infection prevention solutions and services. With annual sales of $12 billion and more than 44,000 associates, Ecolab delivers comprehensive solutions, data-driven insights and personalized service to advance food safety, maintain clean and safe environments, optimize water and energy use, and improve...
Ecolab's Top Stability & Growth Strengths
Profitability: Record sales, earnings per share, and operating margins in 2024 and 2025 indicate sustained margin improvement. Feedback suggests continued expansion is expected in 2026 supported by pricing discipline, productivity, and higher‑margin services.
Strong Market Position & Advantage: Ecolab is consistently characterized as a global leader across water, hygiene, and infection prevention with broad industry reach and high customer retention. Feedback suggests external accolades and large-scale operations reinforce a durable competitive moat.
Innovation-Driven Growth: Expansion into high-growth areas like hyperscale data centers, microelectronics, and life sciences is supported by acquisitions and digital services. Feedback suggests AI-enabled analytics, performance-based contracts, and a growing backlog are fueling future growth.
Beckman Coulter is committed to advancing healthcare for every person by applying the power of science, technology, and the passion and creativity of our teams to enhance the diagnostic laboratory’s role in improving healthcare outcomes. Our diagnostic systems are used in complex biomedical testing, and are found in hospitals, reference laboratories and physician office settings around the globe. Beckman Coulter...
Beckman Coulter Diagnostics's Top Stability & Growth Strengths
Strong Market Position & Advantage: Beckman Coulter Diagnostics is widely recognized as a leader in core‑lab IVD with broad adoption of its chemistry, immunoassay, and automation platforms, supported by Danaher’s top‑tier diagnostics portfolio. Multiple analyses place Danaher (including Beckman) among the leading global diagnostics groups, underscoring substantial installed base and reach.
Innovation-Driven Growth: Recent FDA clearances (e.g., DxC 500i, NT‑proBNP on DxI 9000), Breakthrough Device designation for an Alzheimer’s blood test, and expansion of the DxI 9000 assay menu (including neurodegenerative markers) demonstrate an active pipeline. Research‑use‑only biomarker assays and ongoing menu additions further support platform adoption and reagent pull‑through.
Resilient & Sustainable Growth: Management highlighted mid‑single‑digit growth through 2025, with multiple consecutive quarters of mid‑single‑digit or better growth outside China and expectations for gradual end‑market improvement into 2026. The IVD and clinical chemistry analyzer markets are expanding, providing supportive demand tailwinds.
Avnet is a global electronic components distributor with extensive design, product, marketing and supply chain expertise for customers and suppliers at every stage of the product lifecycle. For the past 100 years, Avnet has helped its customers and suppliers around the world realize the transformative possibilities of technology. Our culture was founded on new ideas and emerging technology. Headquartered in...
Avnet's Top Stability & Growth Strengths
Strong Market Position & Advantage: Avnet is consistently ranked among the top global authorized distributors and is one of the top two in North America, reflecting significant scale and purchasing leverage. Fortune 500 standing and multi‑billion‑dollar revenue reinforce leadership across regions and channels.
Strong Revenue Growth: FY2026 results show broad‑based year‑over‑year increases (e.g., Q2 up ~12% and Q3 up ~34%) across regions and both operating groups, with Q4 guidance implying further sequential gains. Momentum spans Electronic Components and Farnell, led by Asia with the Americas and EMEA returning to growth.
Diversified Revenue Streams: A dual‑channel model combining broadline Electronic Components with high‑service Farnell/Newark extends coverage from prototyping to volume production. Multi‑brand, global reach supports participation across varied end markets and regions, reducing reliance on any single vector.
Ingram Micro helps businesses Realize the Promise of Technology™. It delivers a full spectrum of global technology and supply chain services to businesses around the world. Deep expertise in technology solutions, mobility, cloud, and supply chain solutions enables its business partners to operate efficiently and successfully in the markets they serve. Unrivaled agility, deep market insights and the trust and...
Ingram Micro's Top Stability & Growth Strengths
Strong Revenue Growth: Company updates show net sales grew in FY2025 and continued to rise year over year into early 2026, with multiple consecutive growth quarters during 2025. Feedback suggests momentum was broad‑based across regions and core lines such as Cloud, notebooks/endpoint, and Advanced Solutions.
Strong Market Position & Advantage: Industry coverage consistently places the company among the top two global IT distributors by revenue, reinforced by deep vendor relationships and extensive geographic reach. Feedback suggests this leadership position supports ecosystem influence and partner access across hardware, software, and cloud.
Innovation-Driven Growth: Management highlights the Xvantage digital platform and cloud marketplace as drivers improving partner experience and sell‑through. Evidence in the updates links platform investment to gains in Cloud and services and to the return to year‑over‑year growth exiting 2024 and through 2025.
At OPKO Health, we seek to serve unmet patient needs through our first in class products, comprehensive diagnostics laboratories, robust research and development pipeline, and unique pharmaceutical business solutions. The entrepreneurial acumen of our founder and CEO, Dr. Phillip Frost, has led to the development of a diverse healthcare company flexible enough to adapt to evolving patient needs. We are proud...
Biorasi is a customer-focused, full-service, contract research organization (CRO) that delivers fast and flexible solutions across global clinical trials to maximize speed-to-market for its sponsors. As the leader in neurology, nephrology, dermatology, and the rare and urgent disease market, Biorasi sets new standards for speed, agility, and quality in patient enrollment, decentralized trials, and data transparency. It is Biorasi’s mission to...
Quotient Sciences is a global contract research, development, and manufacturing organization (CRDMO) supporting pharmaceutical and biotechnology companies. Its integrated services span early drug development, candidate selection, first-in-human clinical studies, formulation, clinical research, and commercial manufacturing. By combining scientific expertise, data-driven solutions, and collaborative program management, the company helps emerging biotechs and large pharma advance therapies efficiently from molecule to patients.
At Ultragenyx, we fundamentally believe that taking real impactful action to care for the needs of patients and our people is always the right thing to do. To achieve this goal, our vision is to lead the future of rare disease medicine. For us, this means going where other biopharma companies won’t go – challenging the status quo and creating...
Ultragenyx's Top Stability & Growth Strengths
Resilient & Sustainable Growth: Feedback suggests revenues are on a multi-year upward trajectory, with 2025 growth and a guided step-up in 2026 from current products. The outlook is positioned as durable because guidance excludes unapproved products, implying the existing portfolio is expected to carry baseline growth.
Future-Ready Strategy: Feedback suggests the company is actively building toward future launches through multiple late-stage clinical programs and clear near-term catalysts. The approach emphasizes leveraging the existing commercial organization while advancing new programs into the clinic on a regular cadence.
Cost & Operational Efficiency: Feedback suggests operating discipline is increasing via a strategic restructuring and explicit expense management priorities. The stated target of reaching GAAP profitability by 2027 indicates a focus on improving operating leverage while preparing for pipeline-driven launches.
Watsco, Inc. is the largest distributor of air conditioning, heating, and refrigeration equipment and related parts and supplies in the HVAC/R distribution industry. The company serves over 125,000 contractor-customers through nearly 700 locations across the Americas, providing essential, sustainable comfort to families and businesses while driving the digital transformation of the industry through technology investments.
Tropic Supply, Inc. is a family-owned and operated business and the largest independent wholesale distributor of HVAC and refrigeration equipment and supplies in Florida. Founded in 1973, the company provides sales, exceptional service, and technical support to contractors throughout the state, operating numerous resource centers to serve the air conditioning and refrigeration industries.
Gulfeagle Supply is a national full line distributor of residential and commercial roofing and building products that offers jobsite delivery to our customers. The company was originally founded as Gulfside Supply, Inc. in 1973 by Mr. Jim Resch. The company started in Tampa, Florida with one branch and has grown to over 110 locations nationwide. This growth has come from...
Vitrolife Group is a global provider of medical devices and genetic testing services for reproductive health and assisted reproduction. The company develops, manufactures, and markets fertility products and advanced software, including time-lapse incubators and embryo evaluation systems. Its mission is to help people fulfill the dream of having a healthy baby, supporting fertility clinics and patients worldwide through innovation and...
Vitrolife Group's Top Stability & Growth Strengths
Profitability: Net income and EPS are described as rising sharply, with gross and EBITDA margins expanding materially, indicating stronger bottom-line performance.
Cost & Operational Efficiency: Disciplined cost control, headcount reductions, and strategic pricing are presented as key actions that improved margins and operational performance.
Strong Market Position & Advantage: The company is often characterized as a leading global player in IVF and reproductive health, supported by a broad portfolio and global reach.
Tenet Healthcare Corporation (NYSE: THC) is a diversified healthcare services company headquartered in Dallas. Our care delivery network includes United Surgical Partners International, the largest ambulatory platform in the country, which operates ambulatory surgery centers and surgical hospitals. We also operate a national portfolio of acute care and specialty hospitals, other outpatient facilities, a network of leading employed physicians and...
ScanSource is a leading hybrid distributor connecting devices to the cloud and accelerating growth for partners across hardware, software, connectivity and cloud. Our partners include value-added resellers (VARs), sales partners or agents, independent sales organizations (ISOs), and independent software vendors (ISVs). We are proud of the relationships we build with our partners, and we strengthen these bonds through transparency that...
ScanSource's Top Stability & Growth Strengths
Diversified Revenue Streams: Two operating segments and a growing recurring-revenue mix (about one-third of gross profit) indicate diversification beyond commodity hardware. Intelisys & Advisory aggregates UCaaS/CCaaS, connectivity, security and cloud marketplaces, broadening services exposure.
Healthy Cash Flow: Free cash flow strength is evidenced by roughly $124M TTM by Q3 FY2026 and a raised FY2026 outlook to at least $90M, alongside share repurchases. These signals point to solid cash conversion even amid uneven top-line trends.
Profitability: Gross margin expanded to 13%+ with gross profit rising in recent quarters, and FY2025 showed improved non-GAAP profitability despite lower revenue. The shift toward higher-margin, recurring services appears to support earnings durability.
MMS is an award-winning, global clinical research organization (CRO) that supports leading pharmaceutical and biotech companies as well as many smaller enterprises across our spectrum of services. Having completed more than 50 submissions for drug approval over the last 5 years, we remain a top choice for sponsors who are looking for innovation and demand high quality from their CRO...































